Abstract
Introduction
The economic burden of end-stage kidney disease (ESKD) continues to grow substantially. Future projections are for an increasing prevalence of ESKD globally, driven by an ageing population and the rising number of people with diabetes mellitus, hypertension and obesity [1] [2] [3] . End-stage kidney disease is treated with renal replacement therapy (RRT), namely transplantation or dialysis. For most people with ESKD, transplantation options are limited and dialysis offers a life-extending yet expensive treatment. There are two main forms of dialysis, haemodialysis (HD) and peritoneal dialysis (PD). Haemodialysis (which includes conventional HD, haemofiltration and haemodifiltration) is most commonly undertaken in a dependent fashion by clinical staff at a facility but can also be performed independently by the patient in his/her home. Peritoneal dialysis is performed independently most commonly at home [refer to Appendix 1 of the Electronic Supplementary Material (ESM) for further description of dialysis modalities].
Worldwide, more than 2.5 million people were treated for ESKD in 2015 [4] , this number is projected to more than double to close to 5 million people by 2030, with the highest growth in Asia [5] . Many countries now face increasing demand for dialysis services and are thus faced with the need for low-cost treatments. Facility HD is the most common form of dialysis treatment in nearly all countries, with rates of home HD ranging from 0 to 18% in higher income countries such as Australia and New Zealand, and PD rates ranging from 0 to 30% in New Zealand, Qatar, Thailand and Colombia [4] . In an attempt to reduce the costs of ESKD, a number of countries have more recently initiated 'home dialysis'-first policies to encourage patients away from facility dialysis [6, 7] although the cost effectiveness of this approach is uncertain. Understanding the cost effectiveness of different dialysis modalities therefore has important implications for countries wanting to establish or expand RRT programmes and for countries struggling with the demand of the increasing dialysis population.
A number of costing studies have been performed regionally; however, many are not full economic evaluations. Despite the significance of these costs and the implementation of 'home dialysis'-first policies, to our knowledge, there has been no systematic review of economic evaluations of all dialysis modalities. Rather, reviews to date have focussed on HD and have not included PD [8, 9] . The aim of this study is therefore to review all published cost-effectiveness analyses comparing all alternative dialysis modalities for people with ESKD.
Methods
We conducted a systematic review by searching the following databases: MEDLINE (Ovid); National Health Service Economic Evaluation Database (NHSEED); Health Technology Assessment Databases of Centre of Review; The Cochrane Library (CDSR, CCTR, DARE); and Econlit, from January 2000 to December 2017 for economic evaluations comparing alternative dialysis modalities. Articles prior to 2000 were excluded as they were considered less relevant to contemporary dialysis and healthcare systems because of technological improvements and increasing costs. The search strategy used Medical Subject Headings (MeSH) terms and a range of text words relevant to the identification of publications that included treatment by all modalities of maintenance dialysis and text words relevant to costing studies and economic evaluations (the MEDLINE search strategy is included as Appendix 2 in the ESM).
The titles and abstracts of potentially relevant studies were read by two authors (MH, RW) to identify articles for full-text review. Full-text citations were reviewed by MH and RW and where there was uncertainty about eligibility, were independently assessed by KH using predefined criteria. Studies were included if they were economic evaluations and provided comparative information on the costs, health outcomes and cost-effectiveness ratios of at least two alternative dialysis modalities. Exclusion criteria were: descriptive costing studies, studies with no comparator, studies that addressed dialysis-related complications, review or opinion papers, analyses of paediatric populations, and studies involving haemofiltration or haemodiafiltration. Because of resource limitations, citations published in languages other than English were excluded.
We extracted the following data from included papers: location and setting; publication year; dialysis modality; type of economic evaluation; economic evaluation methods used (model or trial based); perspective of analysis; time horizon of analysis; country and reference year of costs; health outcomes; costs reported; incremental cost-effectiveness ratios (ICERs); and sensitivity analysis. The completeness of reporting of all included studies was assessed by RW and MH using the 24-item Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist [10] . Figure 1 represents the results of the literature search. The initial search identified 2266 citations. Sixteen economic evaluations comparing alternative dialysis modalities were identified for inclusion after excluding duplicate and ineligible publications.
Results

Literature Search
Characteristics of Included Studies
Characteristics of included studies are summarised in Table 1 . Eight of the 16 studies were modelled analyses using Markov models, four studies were single-centre studies, three were multi-centre studies and one was a trial-based analysis. Two studies reported conducting a cost-effectiveness analysis (CEA), eight conducted cost-utility analyses (CUAs) and six studies reported conducting both a CEA and CUA. When reported, the study time horizons varied from 3, 5, and 10 years to lifetime horizons.
Most studies were conducted in Europe (n = 6, 38%), Canada (n = 3, 19%), the UK (n = 2, 13%) and Singapore (n = 2, 13%), and one each from Indonesia, Malaysia and Australia. Ministry of Health or government funding was most common (n = 8, 50%), followed by industry funding (n = 5, 31%), and the remaining three studies (19%) did not report funding. Most studies were conducted from a healthcare funder perspective (n = 11, 69%), four (25%) studies were conducted from both a healthcare funder and a societal perspective and one study from a societal perspective only. The majority of studies were published in nephrology journals (n = 9, 56%), others were in healthcare policy journals (n = 3, 19%) and general healthcare journals (n = 4, 25%).
The 16 studies included in our review are described in detail in Table 2 and discussed below. Studies often examined costs and health outcomes of multiple dialysis modalities, and unfortunately many reported average cost effectiveness (total costs/total health outcomes) rather than calculating ICERs. Additionally, the variability in context (for example, high-vs. low/middle-income country) and perspective hampers our ability to draw definitive conclusions about the incremental cost effectiveness of alternative dialysis modalities.
Afiatin et al. (2017)
A CEA and CUA was undertaken in Indonesia by Afiatin et al. [11] to inform policy as part of the implementation of a national health insurance scheme. A Markov model was 
Fifteen Dimension quality-of-life instrument developed using local Indonesian and international data to estimate the cost effectiveness of a PD-first policy and a HD-first policy compared with supportive care. The supportive care alternative resulted in 0.21 life-years (LYs) or 0.076 quality-adjusted life-years (QALYs). The PD-and HD-first policies both generated 5.93 LY and 4.40 and 4.34 QALYs, respectively, in 52 patients each, reflecting higher utility values assumed for PD compared with HD (0.82 vs. 0.70). From a societal perspective, total costs of supportive care were 1.7 million IDR, PD-first policy was 696.6 million IDR and HD-first policy was 735.4 million IDR. From a healthcare provider perspective, the total costs were 1.1 million IDR, 674.1 million IDR and 672.4 for supportive care, PD-first and HD-first, respectively. When compared with supportive care, the ICER of the PD-first policy was 193 million IDR per QALY, and 207 million IDR per QALY for the HD-first policy. The results of the one-or multi-way sensitivity analyses are not reported; however, the probabilistic analysis indicated that at a willingness to pay of 43 million IDR, supportive care was the preferred option, with the PD-first policy being the preferred option if the willingness to pay was more than 190 million IDR.
Beby et al. (2016)
Beby et al. [12] developed a Markov model using local Dutch and international data to compare conventional incentre HD (ICHD) and conventional home HD and highdose ICHD and high-dose home HD. The authors assessed cost differences between high-dose home HD and conventional ICHD in relation to the differences in clinical effectiveness and used this ratio to determine the ICER (cost per QALY gained). The ICER for high-dose home HD compared with conventional ICHD was €3248 per QALY gained. A second analysis also showed conventional home HD to be less costly per patient (€3063) than conventional ICHD with a higher 0.249 QALY and therefore dominant. The authors concluded conventional home HD to be cost saving compared with conventional ICHD; however, the clinical benefit of high-dose home HD was over two times greater.
Gonzalez-Perez et al. (2005)
Gonzalez-Perez et al. [13] developed a Markov model using previously published clinical and cost data and compared the health services costs and outcomes of hospital, satellite and home HD in Scotland. Two main analyses were conducted: [1] same duration and frequency of HD for all modalities and [2] a short daily home HD schedule. For analysis 1, average per patient costs over 5 years of home HD were estimated to be £47,657 and £63,539 over 10 years, and the average per-patient costs for satellite HD were £46,001 and £62,054, both comparing favourably to hospital HD with corresponding costs of £48,254 at 5 years and £65,131 at 10 years. Total QALYs per patient at 5 years were 2.32, 2.08 and 1.69 for home HD, satellite HD and hospital HD, respectively; the corresponding QALYs at 10 years were 3.45, 3.03 and 2.47. Home HD was both less costly and more effective (dominant) compared with hospital HD at both time points. The ICERs of home HD compared with satellite HD were £6665 and £3943 per QALY gained, at 5 years and 10 years, respectively. For analysis 2, assuming short daily home HD, the ICERs of home HD compared with hospital HD were £7586 and £6696 per QALY gained at 5 years and 10 years, respectively. When comparing home HD to satellite HD, these increased to £30,188 and £22,515 per QALY gained at 5 years and 10 years, respectively. The authors report limited one-way sensitivity analyses, under all scenarios examined, home HD was less costly and more effective than hospital HD. The analysis is reliant on indirect data on utility [14] with a relatively high value of 0.81 for home HD compared with 0.66 for ICHD.
Haller et al. (2011)
Haller et al. [15] developed a Markov model of RRT (including HD, PD and transplant) to examine the cost effectiveness of two alternative RRT modality uptake strategies, compared to current practice in Austria. Two hypothetical uptake strategies were modelled: Strategy 1, 20% of patients with incident ESKD receiving PD; and Strategy 2, 20% of patients with incident ESKD receiving PD and an additional 10% for pre-emptive transplant from a living donor. These strategies were compared to the current practice of 90.6% of new patients with ESKD receiving HD, 7.2% of patients receiving PD, 0.1% of patients receiving transplant from living donors and 2.1% of patients receiving transplant from deceased donors. Transition probabilities were estimated from the Austrian Dialysis and Transplant Registry and quality of life (QOL) was based on published estimates [14] . Compared to current practice over the next 10 years, Strategy 1 (20% of patients with incident ESKD receiving PD) would decrease costs by €26 million and gain 488 LYs and 839 QALYs; Strategy 2 (increasing PD by 20% and pre-emptive transplant by 10%) would decrease costs by €38 million, and gain 1780 LYs and 2242 QALYs. A one-way sensitivity analysis indicated the most influential parameters to be the cost of PD, costs and transition probability for transplantation (after 25 months after transplantation), and QALY weights. Strategies remained dominant over current practice under all sensitivity analyses tested; a probabilistic sensitivity analysis was not reported.
Hooi et al. (2005)
A multi-centre study by Hooi et al. [16] was conducted to determine the costs and cost per LY on HD and continuous ambulatory peritoneal dialysis (CAPD). A sample of 30 HD and 30 CAPD patients was used to estimate healthcare utilisation (including clinic, hospitalisation and pharmaceutical, which included erythropoietin-stimulating agents). It is however unclear how these patients were selected, and whether they were representative of patients treated with these modalities. Survival on dialysis was calculated using the National Renal Registry data to estimate life expectancy for each modality. The mean cost per HD treatment was RM169 (range: RM79.61-475.79); the mean cost per month of CAPD was RM2084 (range: RM1400-3200). Overall, patients estimated life expectancy for CAPD was 5.21 years, the life expectancy for HD was 10.96 years with the difference between modalities being closer in older patients. Unfortunately, the ICERs relative to a comparator are not reported, rather average cost effectiveness ratios (total costs/ total survival) for each modality separately (RM 31,634.93 for CAPD and RM33,642 for HD).
Howard et al. (2009)
The multi-cohort Markov model of incident and prevalent Australian RRT patients by Howard et al. [17] compared costs and outcomes of increasing home-based dialysis in Australia for incident patient cohorts based on patient characteristics and practice patterns from registry data. Health outcomes were measured in LYs and QALYs over a 5-year period (2005-10). Increased uptake of PD and home HD by new patients was modelled, and the analysis suggested that changing practice patterns going forward would result in a 5-year cost saving of AU$46.6 million for HD and AU$122.1 million for PD uptake changes. Incremental costeffectiveness ratios were not calculated as it was assumed that QOL weights (and therefore QALYs) were the same across all dialysis modalities. This is likely to have underestimated the potential health outcome gain with increased home HD and PD, given the assumption regarding comparable utility weights for all dialysis modalities. The authors concluded that both PD and home HD was less costly and at least as effective as current practice patterns. However, setup costs for home HD were not included, and therefore this model may over-estimate home HD cost savings.
Klarenbach et al. (2014)
Klarenbach et al. [18] present a cost-utility analysis to compare costs and outcomes of increasing home nocturnal home HD to conventional HD and a 75% facility model in Alberta, Canada. The model used patient information from the Alberta nocturnal HD randomised controlled trial. Health outcomes were measured in QALYs gained. In the base case, nocturnal home HD was dominant over the conventional dialysis group. Increased uptake of nocturnal home HD led to an incremental cost saving of CAN$6700 and an additional 0.38 QALY. In sensitivity analyses, nocturnal home HD remained dominant when the annual baseline risk of mortality was ≤ 3.6% or when the annual technique failure from nocturnal home to conventional HD was ≤ 6%. Nocturnal home HD was no longer cost effective when the annual probability of technique failure was ≥ 19%. Nocturnal home HD remained dominant up until hospitalisation costs were ≥ 25% higher than conventional HD. Nocturnal home HD remained cost effective when the average patient training time was 8 weeks. Peritoneal dialysis and conventional home HD were only included in the sensitivity analysis. In both cases, ICERs for nocturnal HD were not cost effective at CAN$423,667/QALY and CAN$197,697/QALY, respectively.
Kontodimopoulos et al. (2008)
Kontodimopoulos et al. [19] used a nationally representative sample of patients on HD, PD and undergoing a transplant in Greece to estimate average costs and QALYs based on individual life expectancy. The estimated life-long QALYs were 4.37 for HD and 3.94 for PD. Annual costs per patient were estimated at €36,247 and €30,719, respectively, for HD and PD. The authors did not calculate ICERs of one RRT modality compared to another, or compared to no RRT or supportive care. Instead, they reported average cost per QALY as being higher in HD at €60,353, €54,504 for PD and €11,981 for transplant (lifelong estimate). Evaluation is limited by the absence of ICERs, by the lack of clarity on the representativeness of the selected patients and because the analysis assumes no switches between treatment modalities over a patient's lifetime.
Kroeker et al. (2003)
Kroeker et al. [20] performed an economic evaluation comparing health services costs and outcomes of short daily home HD (n = 10), nocturnal home HD (n = 12), and conventional hospital HD (n = 22) from a Canadian public health system perspective. The study showed that total operating costs per patient-year for nocturnal home HD and hospital HD patients were similar (CAN$74,371 vs. CAN$72,688, respectively), whereas costs for daily home HD patients were lower (CAN$67,281). Treatment supply costs were approximately twice that of the conventional dialysis group in the daily and nocturnal HD patients, whereas average costs for physician consultations, hospitalisations and laboratory tests declined for the daily and nocturnal home HD groups compared with the hospital HD group. The authors concluded that cost savings may be possible by switching patients from conventional HD to either daily HD or nocturnal home HD. An 'annualised' QALY of 0.84 was reported for daily home HD, 0.70 for nocturnal home HD and 0.71 for conventional HD for the prospective part of the study derived using the Health Utility Index. However, no data on QOL are available for the 12 months of the retrospective cost analysis. Based on a simple comparison of retrospective and prospective operating costs per QALY, the authors conclude that daily HD may result in cost savings and health outcomes that are at least comparable to conventional HD. However, this is based on an annualised cost that does not take into account differences in survival or modality changes.
Liu et al. (2015)
Liu et al. [21] developed a Markov model to compare highdose ICHD and home HD (five times weekly) with conventional ICHD (three times weekly) using current and hypothetical HD reimbursement tariffs in England. Model inputs were informed by renal registry data [22] and a literature review [23] . The model determined that high-dose ICHD (five times weekly) is associated with higher patient costs and QALYs (£108,713 and 0.862 higher) compared with conventional ICHD. The ICER for high-dose ICHD compared with conventional ICHD was not cost effective (£126,106/QALY) at a UK willingness-to-pay threshold of £20,000-30,000. High-dose home HD was associated with comparatively lower total costs and QALY increase (£522 and 1.273 less per patient) under the then current tariff of £456/week. At the modelled increase in home HD tariff of £575/week, the ICER for high-dose home HD was £17,404/ QALY compared with conventional ICHD. Therefore, the authors concluded that high-dose home HD had a 62-84% probability of being cost effective at a willingness-to-pay threshold of between £20,000 and 30,000/QALY. Therefore, high-dose HD would only be considered cost effective from the UK payer perspective if conducted at home. There was no comparison between high-dose home HD and conventional HD. The assumptions are similar to Beby et al. [12] .
Malmstrom et al. (2008)
Malmstrom et al. [24] performed an economic evaluation from a societal perspective of patients from a single centre attending self-care HD, comparing the health services costs and outcomes of satellite and home HD in Finland. The costs of home HD and satellite HD were similar (€38, 477 vs. €39,781), with a mean difference of €1304 (95% confidence interval − €6491 to €3883), although there was variation in the relative contribution to total costs across modalities. For example, costs of home installation were higher in home HD patients and average hospital costs were also higher (€4306 per year) for home HD compared with satellite HD, mainly as a result of higher dialysis-related and radiology costs. These were offset by lower annual travel costs for home HD patients of EUR€4802/patient less than satellite HD patients. Home HD patients in this study had longer and more frequent dialysis than their satellite HD counterparts, contributing to the higher dialysis costs for this group. In the satellite HD group, these costs were offset by patient travel costs to attend dialysis. This study did not calculate ICERs.
McFarlane et al. (2003)
McFarlane et al. [25] evaluated QOL and cost utility between home nocturnal HD and conventional ICHD. The authors utilised a prospective costing study and utility-based QOL. Mean total healthcare costs were lower in the home nocturnal HD group compared with the in-centre group (CAN$55,139 vs. CAN$66,367, p = 0.03). Home nocturnal HD was associated with a higher QOL than ICHD (0.772 compared with 0.527, p = 0.03). Cost-effectiveness ratios vs. no treatment (i.e. average cost-effectiveness ratios) were reported. Incremental cost-effectiveness ratios were not reported as nocturnal home HD was both less costly and more effective (dominant) than ICHD. The authors concluded that nocturnal home HD can provide three times as many treatment hours for lower costs compared with conventional ICHD. However, the evaluation is based on annual averages and does not take into account survival, modality changes or complications. Set-up costs for home HD have not been included.
Pike et al. (2017)
Pike et al. [26] aimed to compare the effectiveness and cost effectiveness of PD and HD (in all locations) in Norway, and in a scenario analysis, to estimate savings from starting more patients on PD in Norway and the European Union. Probabilities were informed by data from Norwegian renal registry annual reports and by a systematic review conducted by authors. Utilities for all dialysis modalities were the same with a value of 0.54; disutilities for adverse events (e.g. infection, sepsis, myocardial infarction, angina) were also included. Health outcomes were measured in QALYs. peritoneal dialysis had the lowest cost and slightly lower QALYs over 5 years than HD alternatives. Home HD dominated all other HD modalities and was slightly more effective, although more costly than PD with an ICER of €355,822/QALY gained for home HD compared with PD. Compared to PD, the ICER for hospital HD was €4440,698/ QALY gained; €2,805,785/QALY gained for self-care HD and €5,261,461/QALY gained for satellite HD. The scenario analysis of an increased uptake of PD as the first-choice treatment, along with a corresponding decrease for ICHD resulted in 5-year savings of €32 million for Norway and €10,623 million for the European Union. The authors concluded that PD was the most cost-effective alternative over 5 years and was comparable with HD in efficacy outcomes.
Salonen et al. (2007)
Salonen et al. [27] calculated health system costs and survival of a cohort of 214 dialysis patients attending a single hospital in Finland, commencing RRT (HD or CAPD) between 1991 and 1996. The prime objective of the study was to compare alternate strategies to evaluating cost effectiveness. Authors calculated average cost-effectiveness ratios for HD and CAPD and ICERs for HD vs. CAPD, for a base case, and under three different assumptions for determining effectiveness (different assumptions of censoring for death, modality change and transplant), and duration of followup. Most ICERs for HD compared to CAPD were dominant for CAPD. In four scenarios when the technical failure of modality was considered as death, the ICERs for HD compared to CAPD ranged from $148,303/LY to $444,041/LY. None of the scenarios examined costs and health outcomes after modality changes or transplantation.
Treharne et al. (2014)
A Markov model to evaluate the cost effectiveness of varying levels of PD uptake in patients with incident ESKD compared to current UK practice was developed by Treharne et al. [28] . Scenarios evaluated were increasing PD from the current level of 22% to 39% (Scenario 1) and 50% (Scenario 2), and reducing to 5% PD (Scenario 3). Discounted total costs and QALYs per patient were £96,307 and 2.104 over 5 years and £133,339 and 3.301 over 10 years for the current practice of 22% PD. Increasing use of PD to 39% resulted in 5-and 10-year total per-patient cost savings of £3180 and £4102 compared with 22% and increased QALYs by 0.017 and 0.020, respectively. Peritoneal dialysis uptake of 50% for patients with incident ESKD resulted in 5-and 10-year per-patient cost savings of £5238 and £6758 and QALY increases of 0.029 and 0.033, respectively. If PD uptake decreased from current practice to 5%, there was an increase of £3179 over 5 years and £4098 over 10 years per patient, with commensurate decreases in QALYs per patient of 0.017 and 0.02, over 5 and 10 years, respectively. Results over the longer 10-year time horizon were consistent. A probabilistic sensitivity analysis found a 96.3% probability of cost savings for scenario 1 (PD 39% and ICHD 61%); however, in 38% of the simulations, it was also less effective (i.e. results sat in the south-west quadrant). The cost-effectiveness acceptability curve indicates a high probability (> 95%) of Scenario 1 being cost effective compared with the current practice, even at low willingness-to-pay thresholds.
Yang et al. (2017)
A Markov model to compare HD, CAPD and automated peritoneal dialysis (APD) using clinical data from an observational study and the national renal registry in Singapore was developed by Yang et al. [29] . The base-case analysis in the model was for a hypothetical cohort of non-diabetic 60-yearold patients, and a high-risk group of diabetic 60-year-old patients. In the 60-year-old non-diabetic patients, the ICER for HD vs. CAPD was $S96,447 (US$69,121) per QALY gained, and for APD was $S150,652; in 60-year-old diabetic patients, the ICER for HD compared to CAPD was $S106,281 per QALY gained, and for APD was $S607,750. Sensitivity analysis indicated that the results were most sensitive to the utility of HD; at a willingness-to-pay threshold of $S60,000 (US$43,000) per QALY gained, CAPD had the highest probability of being cost effective in non-diabetic patients.
Completeness of Reporting of Included Studies
Compliance of reporting with the CHEERS check list for the 16 included studies is summarised in Fig. 2 . A common area of noncompliance related to the assessment of uncertainty and characterising heterogeneity. Specifically, uncertainty in single studies (item 20a) and model-based evaluations (item 20b) were fully addressed in 14% and 58% of the applicable studies, respectively, and characterisation of heterogeneity (item 21) in 27% of the 16 studies. Conflict of interest (item 24) was addressed in 44%, adequate description of analytical methods (item 17) in 50% and the time horizon for evaluation (item 8) was clearly described in 63% of the 16 studies. Whilst all studies included comparators, many provided average costs and benefits with 56% not presenting the incremental costs and outcomes (item 19), or calculating ICERs.
Discussion
Providing the growing number of people affected by ESKD with access to dialysis presents a serious health and economic challenge faced by high-, medium-and low-income countries. In lieu of transplantation, increasing provision of home dialysis be it HD or PD is widely viewed as improving QOL, patient-reported outcome measures and reducing costs. However, our review indicates that the economic evaluations to support these assumptions are small in number and the ability to generalise beyond the specific settings and assumptions is limited. Almost all of the 16 evaluations in this review suggest that home dialysis options, whether PD, short daily, nocturnal or high-dose (more frequent) HD, are less costly and seem to offer comparable or better health outcomes than ICHD. Nonetheless, there remain a number of uncertainties that limit the ability to identify which mix of modalities will provide the best outcomes for patients and health budgets in particular settings. Most of the included studies examined costs and health outcomes of multiple dialysis modalities; however, many of the studies reported average cost-effectiveness ratios that are less useful for decision making when moving between alternative modalities compared to ICERs. Future studies also should attempt to detail the cost effectiveness of more realistic and complex RRT journeys, with multiple "switches" between modalities.
The true QOL difference between PD, home HD and ICHD remains poorly defined with a wide range of utility values assumed across the evaluations. Utilities ranged from: 0.55 (17) to 0.82 (11) in PD; 0.53 (25) to 0.71 (20) in conventional HD; and from 0.69 (12) to 0.84 (20) in home nocturnal or daily HD. Data sources for survival and utility include small study cohorts, registry or local data, and indirect evidence from other studies or systematic reviews. A systematic review of utility values in chronic kidney disease published in 2012 [30] supports the general assumption of higher utilities for transplantation; however, it does not support the range of differences assumed in the studies between PD and HD or the differences between home and ICHD. Therefore, we are also limited in our ability to draw conclusions regarding the relative contribution of QOL and survival gains to overall QALYs gained for different modalities.
Where possible, the comparators for assessing cost effectiveness were alternate modalities, frequency or intensity of dialysis, or transplantation. Competing modalities or options that fell outside the prime focus of the evaluations were either excluded or model assumptions were not defined. Similarly, the mix of modalities was often based on arbitrary assumptions rather than reflecting patient characteristics or the healthcare setting. This ranged from assuming all patients started on one or other modality or compared modality percentages that reflect current proportions with arbitrarily assigned increases in the lower cost modality. It is reasonable to assume that the optimal modalities will vary according to health and demographic factors of the patients, particularly costs for patients in rural compared to urban locations, as well as the healthcare setting. Whilst registry data informed a number of the studies as to the probabilities of switching between modalities and death, many studies were based on small data sets or indirect data and assumptions. Many studies also assumed probabilities for switching between modalities do not change with time, whereas this is unlikely to be the case, in particular the switch from PD to HD and from dialysis to transplant and vice versa.
There are limitations and difficulties in comparing studies across countries where service delivery, costs, policies and models of care vary. The studies also used different currencies and financial years, with some not stipulating these, and thus it was not possible to convert findings into a common currency and year for comparison. The majority of included studies were also conducted over a short time horizon, which may not allow for the potential of lower costs as the programme develops efficiencies of scale over time. Additionally, we are limited in our ability to examine the relative contribution to overall costs over time of dialysis compared to other downstream healthcare use across different modalities.
This a growing awareness of the importance of considering the cost of dialysis on patients and their families in the development of renal services [8] . However, societal costs were included in only five studies. Despite these factors, there is an indication that governments and policy makers consider home dialysis options as having the potential to provide a cost-effective alternative compared with facility dialysis. Of importance, this may not apply to low-income countries where access to dialysis supplies, manufacturing of consumables and transportation costs may inflate the price of home-based dialysis; however, more studies in lower income countries are required to determine this. Another factor to consider, particularly in lower income countries, is the societal burden if patients on dialysis are not able to be employed or otherwise contribute to society [31] [32] [33] . Finding cost-effective solutions to the provision of RRT is of crucial importance in low-and middle-income countries. A systematic review by Liyanage et al. [34] estimated that globally in 2010, 4.9 million people needed RRT; however, only 2.6 million people actually received any form of therapy. In addition, they estimated that the number of people receiving RRT would more than double by 2030, providing an additional strain on the provision of treatment. In short, access to RRT is a global problem with the greatest burden being borne by low-income countries, in particular Africa and Asia.
Finally, the establishment costs for home dialysis were not always included. This will favour the cost effectiveness of home dialysis and is particularly problematic when cost and benefits were expressed on an annualised basis.
Conclusions
Based on these findings, we have a number of recommendations. At a fundamental level, there is a lack of registry data in nephrology, particularly in low-and low-middle income countries. We encourage the development of national registries, or more established registries supporting smaller low-income countries to join these registries, as this will enable and encourage future evaluations and research [35] . Registries that also collect a minimum level of data may allow data collection across countries and therefore provide more certainty of comparison and cost effectiveness. We recommend that future studies explore the true costs of home dialysis particularly PD in low-and middle-income countries where the greatest burden of RRT occurs and evaluate at what cost PD would be cost effective to health funders. This may enable governments and policy makers to remove some of the barriers related to access within these countries. Future studies should include a societal perspective and reflect changes in costs and outcomes associated with expected changes in the patient population with time. For example, the increasing age and co-morbidities of dialysis patients will likely be associated with more complications that will in turn limit the viability of PD and home-based HD for these patients.
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